Evaluation Of Fondaparinux (Also Called ARIXTRA) 2.5 mg Subcutaneously Once Daily For The Treatment Of Superficial Thrombophlebitis (Also Known As Superficial Vein Thrombosis)

Inclusion criteria: * Acute symptomatic superficial thrombophlebitis of the lower limbs at least 5 cm long diagnosed by compression ultrasound. Exclusion criteria: * Superficial thrombophlebitis that is within 3 cm from the sapheno-femoral junction, * deep vein thrombosis on ultrasound exam, deep vein thrombosis or pulmonary embolism within last 6 months, treatment for cancer during last 6 months, * anticoagulant medication for more than 48 hours prior to inclusion, * need for oral non-steroidal anti-inflammatory drugs during the study, significant bleeding event during past month, * major surgery within last 3 months, low platelet count (below 100×109/L), * kidney disease (Calculated creatinine clearance \< 30 mL/min), woman of child-bearing potential not using reliable contraceptive method